163.12
price up icon0.00%   0.00
pre-market  プレマーケット:  161.95   -1.17   -0.72%
loading
前日終値:
$163.12
開ける:
$163.88
24時間の取引高:
804.49K
Relative Volume:
0.70
時価総額:
$16.40B
収益:
$3.10B
当期純損益:
$668.60M
株価収益率:
25.08
EPS:
6.5044
ネットキャッシュフロー:
$831.30M
1週間 パフォーマンス:
+1.32%
1か月 パフォーマンス:
+7.14%
6か月 パフォーマンス:
+5.25%
1年 パフォーマンス:
+30.09%
1日の値動き範囲:
Value
$162.22
$165.40
1週間の範囲:
Value
$154.06
$169.57
52週間の値動き範囲:
Value
$122.14
$169.57

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1100)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
2,000
Name
Twitter
Name
次回の収益日
2026-07-29
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NBIX icon
NBIX
Neurocrine Biosciences Inc
163.12 16.48B 3.10B 668.60M 831.30M 6.5044
TAK icon
TAK
Takeda Pharmaceutical Co Adr
15.74 49.29B 29.91B 1.30B 3.49B 0.4056
HLN icon
HLN
Haleon Plc Adr
8.89 40.34B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
33.26 39.81B 17.53B 1.58B 444.18M 1.3457
ZTS icon
ZTS
Zoetis Inc
78.82 33.30B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
544.69 23.34B 3.17B 1.29B 1.01B 27.09

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-24 開始されました Wolfe Research Outperform
2026-01-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-10-21 開始されました Citigroup Buy
2025-07-21 開始されました Truist Buy
2025-07-10 開始されました Goldman Buy
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
Jun 08, 2026

Cerebral Palsy Market Positioned for Significant Commercial Growth by 2036 – DelveInsight | Neurocrine Biosciences, Teva Pharma, Bundang CHA Hospital, Jazz Pharma - Barchart.com

Jun 08, 2026
pulisher
Jun 08, 2026

Neurocrine presents tardive dyskinesia treatment data at conference - StreetInsider

Jun 08, 2026
pulisher
Jun 08, 2026

Neurocrine Biosciences director sells $210,071 in stock - Investing.com

Jun 08, 2026
pulisher
Jun 08, 2026

Neurocrine (NBIX) director sells 1,250 shares under Rule 10b5-1 plan - Stock Titan

Jun 08, 2026
pulisher
Jun 08, 2026

Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients - PR Newswire

Jun 08, 2026
pulisher
Jun 08, 2026

Neurocrine reports positive INGREZZA data for TD in patients with IDD - grafa.com

Jun 08, 2026
pulisher
Jun 08, 2026

Neurocrine presents data on tardive dyskinesia treatment - Investing.com

Jun 08, 2026
pulisher
Jun 08, 2026

Neurocrine presents data on tardive dyskinesia treatment By Investing.com - Investing.com Australia

Jun 08, 2026
pulisher
Jun 08, 2026

Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities - PR Newswire

Jun 08, 2026
pulisher
Jun 08, 2026

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Nears Technical Breakout with Near-Perfect Score - ChartMill

Jun 08, 2026
pulisher
Jun 06, 2026

Neurocrine publishes dosing guidelines for CAH treatment drug - Investing.com

Jun 06, 2026
pulisher
Jun 05, 2026

Neurocrine Biosciences Inc. (NBIX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Jun 05, 2026
pulisher
Jun 05, 2026

[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan

Jun 05, 2026
pulisher
Jun 05, 2026

Behavioral Patterns of NBIX and Institutional Flows - Stock Traders Daily

Jun 05, 2026
pulisher
Jun 05, 2026

Does Neurocrine Biosciences’ (NBIX) Rare Disease Push Quietly Rewire Its Endocrine Risk-Reward Profile? - simplywall.st

Jun 05, 2026
pulisher
Jun 05, 2026

Oppenheimer raises Neurocrine Bio stock price target on strong results - Investing.com

Jun 05, 2026
pulisher
Jun 05, 2026

Neurocrine Biosciences Insider Sold Shares Worth $5,770,235, According to a Recent SEC Filing - Moomoo

Jun 05, 2026
pulisher
Jun 05, 2026

Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum - Yahoo Finance

Jun 05, 2026
pulisher
Jun 04, 2026

Neurocrine Biosciences(NBIX.US) Officer Sells US$5.77 Million in Common Stock - Moomoo

Jun 04, 2026
pulisher
Jun 04, 2026

Baird reiterates Neurocrine Bio stock rating on acquisition potential - Investing.com

Jun 04, 2026
pulisher
Jun 04, 2026

Neurocrine (NBIX) HR chief sells 36,937 shares and exercises options in pre-set plan - Stock Titan

Jun 04, 2026
pulisher
Jun 04, 2026

Neurocrine (NBIX) CMO reports RSU vesting and tax share withholding - Stock Titan

Jun 04, 2026
pulisher
Jun 04, 2026

RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX) - Yahoo Finance

Jun 04, 2026
pulisher
Jun 04, 2026

A Look At Neurocrine Biosciences (NBIX) Valuation As New CRENESSITY Data Heads To ENDO 2026 - simplywall.st

Jun 04, 2026
pulisher
Jun 04, 2026

Neurocrine to present two-year Crenessity data at ENDO 2026 - Investing.com UK

Jun 04, 2026
pulisher
Jun 04, 2026

NBIX Stock Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill

Jun 04, 2026
pulisher
Jun 03, 2026

Neurocrine to acquire Soleno Therapeutics for $2.9 billion By Investing.com - Investing.com Australia

Jun 03, 2026
pulisher
Jun 03, 2026

Neurocrine Biosciences shares jump on fresh long-term CRENESSITY data catalyst - Quiver Quantitative

Jun 03, 2026
pulisher
Jun 03, 2026

NBIX Stock Draws Bullish Targets After Soleno Deal - StocksToTrade

Jun 03, 2026
pulisher
Jun 03, 2026

Neurocrine Biosciences Jumps 5.8% Amid Sector-Wide Rally - AlphaStreet

Jun 03, 2026
pulisher
Jun 03, 2026

Two-year CRENESSITY data track CAH hormones, growth and quality of life - Stock Titan

Jun 03, 2026
pulisher
Jun 03, 2026

Goldman Sachs Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $213 - Moomoo

Jun 03, 2026
pulisher
Jun 03, 2026

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Peter Lynch GARP Opportunity with Strong Growth and a PEG Ratio of 0.82 - ChartMill

Jun 03, 2026
pulisher
Jun 02, 2026

NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill

Jun 02, 2026
pulisher
Jun 02, 2026

William Blair Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating - Moomoo

Jun 02, 2026
pulisher
Jun 02, 2026

Neurocrine Biosciences CSO Jude Onyia sells $1.76m in stock - Investing.com UK

Jun 02, 2026
pulisher
Jun 02, 2026

Neurocrine Biosciences chief regulatory officer sells $354,321 in stock - Investing.com UK

Jun 02, 2026
pulisher
Jun 02, 2026

Neurocrine Biosciences CSO Jude Onyia sells $1.76m in stock By Investing.com - Investing.com South Africa

Jun 02, 2026
pulisher
Jun 02, 2026

A Look at Neurocrine Biosciences Inc (NBIX) After 3.8% Decline -- GF Value $183.77 vs Price $154.84 - GuruFocus

Jun 02, 2026
pulisher
Jun 02, 2026

Neurocrine Biosciences chief regulatory officer sells $354,321 in stock By Investing.com - Investing.com Canada

Jun 02, 2026
pulisher
Jun 02, 2026

[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan

Jun 02, 2026
pulisher
Jun 02, 2026

Neurocrine (NASDAQ: NBIX) CRO sells 2,261 shares after option exercise - Stock Titan

Jun 02, 2026
pulisher
Jun 02, 2026

24,965-share Rule 144 sale notice for Neurocrine (NASDAQ: NBIX) - Stock Titan

Jun 02, 2026
pulisher
Jun 02, 2026

Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating By Investing.com - Investing.com South Africa

Jun 02, 2026
pulisher
Jun 02, 2026

Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating - Investing.com

Jun 02, 2026
pulisher
Jun 01, 2026

Form 144: 11,000-share sale notice tied to option exercise (NBIX) - Stock Titan

Jun 01, 2026
pulisher
Jun 01, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 21% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews

Jun 01, 2026
pulisher
May 30, 2026

Neurocrine Biosciences CSO Jude Onyia sells $1.71m in shares By Investing.com - Investing.com Australia

May 30, 2026
pulisher
May 30, 2026

Neurocrine Biosciences CSO Jude Onyia sells $1.71m in shares - Investing.com UK

May 30, 2026

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$15.93
price up icon 0.31%
$23.68
price up icon 0.21%
RDY RDY
$13.23
price down icon 0.08%
RGC RGC
$21.39
price up icon 7.00%
$544.69
price down icon 0.94%
大文字化:     |  ボリューム (24 時間):